Drugs / DuoTrav
last change Feb 2013 re-read 2 minutes ago

DuoTrav

Developed for
ocular hypertension · open-angle glaucoma · glaucoma
Investigated by
Alcon Research · Kasr El Aini Hospital

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) DuoTrav 2006-04-23 europa.eu

Trials 3 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT01696383 Feb 2013 glaucoma, ocular hypertension Alcon Research Withdrawn No outcome recorded
Phase 4 NCT00828906 Feb → Nov 2009 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded
Phase not applicable1 trial
NCT01542710 Jan → Dec 2011 open-angle glaucoma Kasr El Aini Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00862472 Comparator Mar → Jun 2009 ocular hypertension, open-angle glaucoma Alcon Research Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as DuoTrav ClinicalTrials.gov intervention name — accepted as the source's own label NCT00862472
3

NCT00828906

NCT01542710

NCT01696383

Route Topical “DuoTrav Eye Drops” NCT00828906